Servier

Web: servier.com

It is Servier’s ambition to become an innovative and recognized player in oncology through meaningful research and the development of therapeutic compounds that could cure cancer, that could extend life and, importantly, improve the quality of life of people with cancer. Currently, Servier’s portfolio in oncology comprises 19* projects in clinical development for both solid tumors and hematological malignancies with biomarker-led targeted therapies in difficult to treat cancers such as liver-, gastro-intestinal- and pancreatic-cancer as well as subpopulations of more prevalent cancers. Our research portfolio is balanced between monoclonal antibodies and targeted small molecules.
*Data as of May 2021

• Website URL www.servier.com
• LinkedIn URL www.linkedin.com/company/servier/
• Twitter URL twitter.com/Servier
• Facebook URL www.facebook.com/Servier

At present there is no donated content from this sponsor.

ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.